Quo vadis en vacunas: desde la aproximación empírica a la nueva oleada tecnológica

Fernández-Prada, María; Trigo, José Antonio López; Bayas, José M.; Cambronero, Maria Del Rosario

doi:10.1016/j.regg.2019.09.001

Cited by 2 publications

(4 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the central countries, the traditional vaccines-attenuated or inactivated pathogens-were gradually replaced by more sophisticated modern vaccines: second generation-subunit, recombinant, conjugated vaccines-and even third generation-virus like particles, RNA or DNA vaccines, vector vaccines (Corvalán 2010;Fernández et al 2020). As a corollary, the number of jwsr.pitt.edu | DOI 10.5195/JWSR.2021.1049 producers and suppliers of traditional vaccines in developing countries had an exponential increase, representing 86 percent of suppliers worldwide.…”

Section: Biotechnology and Geopoliticsmentioning

confidence: 99%

“…The vaccine designed by the American multinational Pfizer and the German biotechnology company BioNTech is based on the technology of mRNA-messenger ribonucleic acid. These are third-generation vaccines, which had never been tested in humans until the pandemic caused by SARS-CoV-2 (Fernández et al 2020;Navas 2020a). The mRNA vaccines promise a new era in vaccinology and this is due, among other causes, to productive reasons: they are easier to manufacture and scale industrially than any other type of vaccine (Servick 2020).…”

Section: Astrazeneca and Mabxiencementioning

confidence: 99%

See 1 more Smart Citation

Covid-19 and Semi-Periphery

Blinder

Zubeldía²,

Surtayeva

2021

JWSR

View full text Add to dashboard Cite

The SARS-CoV-2 pandemic has disturbed the order of the world-system. While central countries—through their pharmaceutical multinationals—focused on the development of vaccines, semi-peripheral and peripheral countries fulfill another role, either by offering an environment for trials, or by inserting themselves in the hierarchical global order as a hub for research, development, or production of the candidate vaccines. This paper focuses on the analysis of the geopolitics of the world-system regarding production and participation in the clinical trials of vaccines for SARS-CoV-2 of Oxford University-AstraZeneca, BioNTech-Pfizer, and Sinopharm in Argentina. This is a case analysis of the Argentine semi-peripheral context, the local and global pharmaceutical industry, and the geopolitical order. We conclude that Argentina, which has scientific and industrial capabilities to manufacture vaccines, has joined in global value chains on the dependence side, deepening the scientific and technological gap vis-à-vis the central countries.

show abstract

Section: Biotechnology and Geopoliticsmentioning

confidence: 99%

Section: Astrazeneca and Mabxiencementioning

confidence: 99%

Covid-19 and Semi-Periphery

Blinder

Zubeldía²,

Surtayeva

2021

JWSR

View full text Add to dashboard Cite

show abstract

“…Finally, when a regulated e-consultation is used, all clinical information is recorded in the electronic health record (EHR), providing greater security for patients and professionals, especially when compared to informal consultations between professionals, such as curb-side consultations. 7,8 The increase in chronic pathologies -with and without immunodeficiency 8 -and the constant development of new vaccines 9 have increased the need for specialised medical assessments on vaccinology. However, to our knowledge, no use of e-consultation on vaccines (e-CV) has been documented in the scientific literature.…”

Section: Introductionmentioning

confidence: 99%

“…The increase in chronic pathologies – with and without immunodeficiency 8 – and the constant development of new vaccines 9 have increased the need for specialised medical assessments on vaccinology. However, to our knowledge, no use of e-consultation on vaccines (e-CV) has been documented in the scientific literature.…”

Section: Introductionmentioning

confidence: 99%

Preliminary evaluation of an inter-professional e-consultation on vaccines

et al. 2020

Self Cite

View full text Add to dashboard Cite

The aim of this study was to assess the preliminary effectiveness and acceptability of an inter-professional e-consultation on vaccines. We used a quasi-experimental design to introduce an application in electronic health records that allowed primary health providers to launch e-consults to the hospital vaccines unit. A total of 135 e-consults were received during 10 months. E-consults were more frequently about subjects with chronic diseases (82.2%). Most of the e-consults were global (60.7%), that is, to revise a patient’s complete vaccination schedule, whereas 39.3% were specific, that is, to request information regarding a concrete vaccine or serology, with hepatitis vaccines leading the ranking (42.9%). The e-consultation avoided hospital referral in 85.4% of the global e-consults and in 100% of the specific e-consults. Indicators of acceptability were all above nine points (10 points indicated the maximum). The best-rated aspect was the level of recommendation (9.7 ± 0.68 points). In summary, linking primary health-care providers with specialists in vaccines through an e-consultation tool is effective and well-accepted by users.

show abstract

Quo vadis en vacunas: desde la aproximación empírica a la nueva oleada tecnológica

Cited by 2 publications

References 49 publications

Covid-19 and Semi-Periphery

Covid-19 and Semi-Periphery

Preliminary evaluation of an inter-professional e-consultation on vaccines

Contact Info

Product

Resources

About